BioCentury | Apr 20, 2017
Company News

NICE recommends against Darzalex to treat MM

...evidence was "unreliable." The evidence Johnson & Johnson submitted came from the single-arm Phase III SIRIUS...
BioCentury | Jan 12, 2017
Financial News

POC Medical Systems completes venture financing

...POC Medical raised $21 million in a series A round led by BioVentures Investors . Sirius...
BioCentury | Apr 11, 2016
Clinical News

Darzalex daratumumab regulatory update

...and an immunomodulatory agent (IMiD). The recommendation was based on data from the Phase III SIRIUS...
BioCentury | Nov 23, 2015
Clinical News

Darzalex daratumumab regulatory update

...the drug has not yet been approved. The BLA included data from the Phase II Sirius...
BioCentury | Sep 24, 2015
Clinical News

MorphoSys reports responses with MOR202 for MM

...3 stringent complete responses, 10 very good PRs and 18 PRs in the Phase II Sirius...
BioCentury | Sep 14, 2015
Clinical News

Daratumumab regulatory update

...against CD38 (see BioCentury, Sept. 3, 2012). Both applications include data from the Phase II Sirius...
BioCentury | Jul 20, 2015
Clinical News

Daratumumab regulatory update

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...
BioCentury | Jun 15, 2015
Clinical News

Daratumumab regulatory update

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...
BioCentury | Jun 8, 2015
Clinical News

Daratumumab: Additional Phase II data

...Data from 106 MM patients in the 2-part, open-label, international Phase II Sirius MMY2002 trial showed...
BioCentury | Feb 9, 2015
Clinical News

Daratumumab: Preliminary Phase II data

...Preliminary data from the 2-part, open-label, international Phase II Sirius MMY2002 trial in 124 MM patients...
Items per page:
1 - 10 of 51
BioCentury | Apr 20, 2017
Company News

NICE recommends against Darzalex to treat MM

...evidence was "unreliable." The evidence Johnson & Johnson submitted came from the single-arm Phase III SIRIUS...
BioCentury | Jan 12, 2017
Financial News

POC Medical Systems completes venture financing

...POC Medical raised $21 million in a series A round led by BioVentures Investors . Sirius...
BioCentury | Apr 11, 2016
Clinical News

Darzalex daratumumab regulatory update

...and an immunomodulatory agent (IMiD). The recommendation was based on data from the Phase III SIRIUS...
BioCentury | Nov 23, 2015
Clinical News

Darzalex daratumumab regulatory update

...the drug has not yet been approved. The BLA included data from the Phase II Sirius...
BioCentury | Sep 24, 2015
Clinical News

MorphoSys reports responses with MOR202 for MM

...3 stringent complete responses, 10 very good PRs and 18 PRs in the Phase II Sirius...
BioCentury | Sep 14, 2015
Clinical News

Daratumumab regulatory update

...against CD38 (see BioCentury, Sept. 3, 2012). Both applications include data from the Phase II Sirius...
BioCentury | Jul 20, 2015
Clinical News

Daratumumab regulatory update

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...
BioCentury | Jun 15, 2015
Clinical News

Daratumumab regulatory update

...the indication. Janssen said the BLA is primarily supported by data from the Phase II Sirius...
BioCentury | Jun 8, 2015
Clinical News

Daratumumab: Additional Phase II data

...Data from 106 MM patients in the 2-part, open-label, international Phase II Sirius MMY2002 trial showed...
BioCentury | Feb 9, 2015
Clinical News

Daratumumab: Preliminary Phase II data

...Preliminary data from the 2-part, open-label, international Phase II Sirius MMY2002 trial in 124 MM patients...
Items per page:
1 - 10 of 51